Cover Image

Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study

Show other versions (1)

<h4>Background</h4> Nifurtimox-eflornithine combination therapy (NECT) for the treatment of second stage gambiense human African trypanosomiasis (HAT) was added to the World Health Organization's Essential Medicines List in 2009 after demonstration of its non-inferior efficacy compa...

Full description

Saved in:

Bibliographic Details
Main Authors:	Andrea Kuemmerle (Author), Caecilia Schmid (Author), Sonja Bernhard (Author), Victor Kande (Author), Wilfried Mutombo (Author), Medard Ilunga (Author), Ismael Lumpungu (Author), Sylvain Mutanda (Author), Pathou Nganzobo (Author), Digas Ngolo Tete (Author), Mays Kisala (Author), Christian Burri (Author), Severine Blesson (Author), Olaf Valverde Mordt (Author)
Format:	Book
Published:	Public Library of Science (PLoS), 2021-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.
by: Caecilia Schmid, et al.
Published: (2012)

Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo.
by: Andrea Kuemmerle, et al.
Published: (2020)

Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study.
by: Andrea Kuemmerle, et al.
Published: (2021)

Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series.
by: Francesco Checchi, et al.
Published: (2007)

Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma brucei.
by: Isabel M Vincent, et al.
Published: (2012)

Trypanosome SL-RNA detection in blood and cerebrospinal fluid to demonstrate active gambiense human African trypanosomiasis infection.
by: Ipos Ngay Lukusa, et al.
Published: (2021)

NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness.
by: Oliver Yun, et al.
Published: (2010)

Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study
by: Victor Kande Betu Ku Mesu, DPH, et al.
Published: (2021)

Co se čte a co se nečte?
by: Eva Minaříková
Published: (2022)

Enantiospecific antitrypanosomal in vitro activity of eflornithine.
by: Mikael Boberg, et al.
Published: (2021)

Diagnostic accuracy of PCR in gambiense sleeping sickness diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study.
by: Stijn Deborggraeve, et al.
Published: (2011)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
by: Miriam Rolon, et al.
Published: (2022)

Cardiac alterations in human African trypanosomiasis (T.b. gambiense) with respect to the disease stage and antiparasitic treatment.
by: Johannes A Blum, et al.
Published: (2009)

Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial
by: Jacques Pépin, et al.
Published: (2000)

Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo
by: Manica Balasegaram, et al.
Published: (2006)

Identification of transport systems involved in eflornithine delivery across the blood-brain barrier
by: Christopher P. Watson, et al.
Published: (2023)

Eflornithine Hydrochloride-Loaded Electrospun Nanofibers as a Potential Face Mask for Hirsutism Application
by: Shuruq S. Almuwallad, et al.
Published: (2023)

Performance of parasitological and molecular techniques for the diagnosis and surveillance of gambiense sleeping sickness.
by: Dieudonné Mumba Ngoyi, et al.
Published: (2014)

Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease.
by: Samanta Moroni, et al.
Published: (2019)

Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina.
by: David Vizcaya, et al.
Published: (2021)

Negativation of Trypanosoma cruzi PCR within Six Months after Treatment of a Child with Nifurtimox.
by: Lauren Pull, et al.
Published: (2015)

Gambiense sleeping sickness: re-emerging and soon untreatable?
by: Simon Van Nieuwenhove
Published: (2000)

Gambiense sleeping sickness: re-emerging and soon untreatable?
by: Simon Van Nieuwenhove

The natural progression of Gambiense sleeping sickness: what is the evidence?
by: Francesco Checchi, et al.
Published: (2008)

Evaluation of the micro-CATT, CATT/Trypanosoma brucei gambiense, and LATEX/T. b. gambiense methods for serodiagnosis and surveillance of human African trypanosomiasis in West and Central Africa
by: Truc Philippe, et al.
Published: (2002)

Sensitivity and Specificity of a Prototype Rapid Diagnostic Test for the Detection of Trypanosoma brucei gambiense Infection: A Multi-centric Prospective Study.
by: Sylvie Bisser, et al.
Published: (2016)

Village-scale persistence and elimination of gambiense human African trypanosomiasis.
by: Christopher N Davis, et al.
Published: (2019)

Accuracy of five algorithms to diagnose gambiense human African trypanosomiasis.
by: Francesco Checchi, et al.
Published: (2011)

Monitoring the Progress towards the Elimination of Gambiense Human African Trypanosomiasis.
by: Pere P Simarro, et al.
Published: (2015)

Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal.
by: Vincent Jamonneau, et al.
Published: (2012)

Need of entomological criteria to assess zero transmission of gambiense HAT.
by: Philippe Solano
Published: (2021)

Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia.
by: Fiorella Bianchi, et al.
Published: (2015)

First WHO meeting of stakeholders on elimination of gambiense Human African Trypanosomiasis.
by: Peter Holmes
Published: (2014)

A Primate APOL1 Variant That Kills Trypanosoma brucei gambiense.
by: Anneli Cooper, et al.
Published: (2016)

Syndromic algorithms for detection of gambiense human African trypanosomiasis in South Sudan.
by: Jennifer J Palmer, et al.
Published: (2013)

Identification of peptide mimotopes of Trypanosoma brucei gambiense variant surface glycoproteins.
by: Liesbeth Carolien Van Nieuwenhove, et al.
Published: (2011)

Neural Damage in Experimental Trypanosoma brucei gambiense Infection: The Suprachiasmatic Nucleus
by: Chiara Tesoriero, et al.
Published: (2018)

Accuracy of individual rapid tests for serodiagnosis of gambiense sleeping sickness in West Africa.
by: Vincent Jamonneau, et al.
Published: (2015)

Early prediction of treatment efficacy in second-stage gambiense human African trypanosomiasis.
by: Gerardo Priotto, et al.
Published: (2012)

The impact of vector migration on the effectiveness of strategies to control gambiense human African trypanosomiasis.
by: Martial L Ndeffo-Mbah, et al.
Published: (2019)